Obsidian Therapeutics
@Obsidian_Tx
Unlocking the promise of cell & gene therapy
ID:710519103581233153
http://obsidiantx.com 17-03-2016 17:32:09
288 Tweets
1,4K Followers
147 Following
Today at 3:40 pm, Jan ter Meulen, M.D., Ph.D., CSO, will present “Armoring TIL for Increased Persistence, Potency and Impact on the Tumor Microenvironment” during the IO360° Summit The Conference Forum.
Check out the full agenda at theconferenceforum.org/conferences/im…
Our partnership with Vertex Pharmaceuticals was featured in @nature as one of the top 20 strategic alliance deals in the #celltherapy and #genetherapy space. The collaboration leverages our cytoDRiVE technology to discover controllable genetic therapies. Read more: bit.ly/3FgkAqQ
.FierceBiotech covered our partnership extension with Bristol Myers Squibb. The collaboration extension provides the exclusive option for BMS to in-license rights for #celltherapy candidates utilizing our #cytoDRiVE technology to control the expression of CD40L. bit.ly/3DQrqT2
Today our poster “Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models” will be presented by our team at #SITC .
Learn more about all our posters at Society for Immunotherapy of Cancer: obsidiantx.com/news-releases/…
Today we announced that we will be presenting #preclinical data highlighting our recent #cytoDRiVE platform and pipeline advances during the poster sessions at #SITC22 Society for Immunotherapy of Cancer.
For more details on the presentations and abstract summaries: obsidiantx.com/news-releases/…
#InvestorConference - Our management team will be attending the SVB Leerink Biopharma Private Company Connect virtually October 26 –27.
Our #CEO , Paul Wotton, spoke with @MattPillar of the #BusinessofBiotech #podcast about Obsidian’s path to FDA clearance of the IND application for #OBX115 this past summer.
Listen BioProcess Online: bioprocessonline.com/doc/ind-for-ti…
As reported by Becca Carballo of Houston Chronicle – #OBX115 received IND clearance, and clinical trials in #metastaticmelanoma will begin soon. The research teams hope they have found a technique that is more effective without harsh side effects: bit.ly/3dskmkP